The transition from LC3B-I to LC3B-II was also enhanced in a dose-dependent manner and time-dependent manner (Fig. 1d–e and Supplementary Figure S3d), and real for different cancer cell lines (Supplementary Figure S1e). Here, MAP1LC3B is linked to cancer.